© Reuters. FILE PHOTO: Fresenius headquarters in Dangerous Homburg close to Frankfurt, Germany, February 27, 2018. REUTERS/Ralph Orlowski
BERLIN (Reuters) – Kidney dialysis supplier Fresenius Medical Care (NYSE:) (FMC (NYSE:)) on Sunday revised down its forecast for 2022, anticipating web earnings to say no this 12 months, dragged down by rising labour prices and a slower than anticipated restoration in North America enterprise.
The corporate now expects web earnings to say no within the high-teens to mid-20s share vary this 12 months, down from its earlier outlook of a high-teens share drop. It nonetheless expects income to develop at a low single digit share fee.
FMC stated web earnings dropped 16% in third quarter to 230 million euros ($229.15 million) whereas working earnings fell by 7% to 472 million euros within the quarter.
($1 = 1.0037 euros)
